July 2, 2012Date Released: 2 July 2012
MESSAGE FROM THE DIRECTOR
Stan Gerson, MD
This year, the Senior Leaders decided the retreat should focus on the scientific and coordination efforts in preparation for the Cancer Center site visit, which will be held October 23 in Thwing Hall on CWRU campus.
The renewal application, all 1560 pages, the effort of over 60 individuals, and supporting the efforts of over 80 individual faculty members of the Cancer Center, has been received by the NCI Cancer Centers Branch. They will be distributing this grant to 24-27 reviewers. Many of these individuals serve as leaders of other cancer centers, are on the parent committee, were present at our last review, or are scientific or shared resource experts in their fields.
The purpose of the site visit is to provide the reviewers and the NCI with a hands-on impression of the coordination efforts undertaken by the cancer center. Of particular interest is our inter-institutional effort, because we are the second largest consortium cancer center in the country (behind Harvard). We will address many issues at the retreat, from scientific content of the program presentations to approaches to showcase interprogrammatic cross disciplinary efforts, clinical research, minorities, and attention to the new guidelines which will impact our review.
The Cancer Center Retreat will be held July 10 from 10 am - 4 pm in Dively. All Senior Leaders, Program Leaders, Shared Resource Directors and managers, cancer center administration, clinical research office, and hospital CTU leaders and directors should plan to attend. If you are not sure whether this retreat is appropriate for you, please contact me directly at email@example.com.Cancer Genomics
Cancer Center leaders met with the Board of Governors for the Cancer Center on June 20. The major topic of discussion was moving forward with a strategic initiative in cancer genomics across the institutions. From this discussion, a consensus was achieved that prioritizes efforts to develop a robust program across the institutions for evaluating the genomes of cancer patients and their cancers to address the potential for precision evaluation, decision-making, and treatment of cancer. This process will evolve over the next four months as we develop a more focused strategic plan and business plan for implementation of the various aspects of cancer genomics.
The individuals in these discussions welcome your input regarding the next steps that will be taken as the plans mature. Please contact me or one of the following individuals: Drs. Sandy Markowitz, Charis Eng, Lyndsay Harris, Ruth Keri, Brian Bolwell, Jarek Maciejewski, Cliff Harding, Neal Meropol, Rob Dreicer, Jill Barnholtz-Sloan, and Eric Hsi.Reorganization of the Athymic Animal and Xenograft Facility
The Cancer Center has embarked on an ongoing effort to reorganize the Athymic Animal and Xenograft Core Facility for the benefit of users throughout the center. As these changes evolve, we will keep the membership up to date through the newsletter and revisions to the website.
Leadership: Dr. Daniel Lindner is Director of the facility. He continues to be based at Taussig Cancer Institute (TCI) providing support for human tumor experiments, angiogenesis studies, and pharmacokinetic studies in mice. He will assist members in experimental design and in use of the facility.
Sites: As users appreciate, there are two sites – one at TCI and the other within the Animal Research Core of CWRU. A full listing of services provided by both sites is listed on the core website.
Manager: Kristen Lozada has been named Manager of the Facility at CWRU. This facility will continue to breed and house athymic nude mice (NCRnu/nu), NOD-SCID mice, and other immunodeficient animals, and will develop a suite of services that will be listed on the website within the next week. Kristen has many years of experience with xenograft and animal experimentation, working with Dr. Ruth Keri, who will continue to provide guidance. Please contact Kristen to design experiments at CWRU.
Among services provided are drug administration (IV, IM, IP, SC); blood draw (cardiac, retro-orbital); xenografts, including subcutaneous or orthotopic; transplantation into a variety of organs: mammary fat pad, ovary, oviduct, kidney, and brain (additional sites pending); tail vein and cardiac tumor cell injection, mouse weight and tumor caliper measurements; delivery of mice to imaging core; imaging of uciferase-labeled tumors; organ and tissue harvest; and IACUC protocol consultation.
IACUC protocol approval: All investigators using the facility must have approval from the IACUC to carry out their specific experiments, referencing the IACUC protocol of the facility. The Athymic Animal and Xenograft Core Facility protocol covers the breeding of mice, but your experiment specific information, such as cell lines, numbers of animals, and procedures, whether done in the core facility or in the PI's laboratory, must be listed in your own protocol. Kristen is available to help you to write your protocol.
Mouse colony: The SCID mouse colony is being re-established, and Dr. Keri and Kristen expect that by January 2013 the core will be able to promptly meet investigators' needs for mice. Mice are available during the time up to January, but on a more limited basis. Mice purchased through approved vendors can be housed in the facility.
CASE CCC IN THE NEWS
Cancer Drug Shows Promise in Reversing Alzheimer's Symptoms in ...
Mentor High grad's life changes after previously undetected brain ...
Oncomatrix, National Jewish Health and Case Western Reserve University Join Forces to Attack Invasive Tumors
ANNOUNCEMENTSReminder: Reporting Clinical Trial Results in clinicaltrials.gov
A federal mandate requires reporting of clinical trial results inclinicaltrials.gov. U.S. Public Law 110-85 (Food and Drug Administration Amendments Act of 2007), Title VIII, Section 801, mandates that certain clinical trials have to be registered and results have to be reported in clinicaltrials.gov. Clinical trial results registration became effective as of September 2008.
The function of clinical trial and result registration is centralized within The Case CCC and April Firstencel, the Case CCC Registration Coordinator, has been working with investigators, study staff and statisticians to ensure that Case CCC complies with federal requirements. This announcement serves as a reminder about our on-going efforts and the need for everybody's assistance and collaboration to meet these obligations. Please direct questions to April Firstencel, Research Coordinator for clinicaltrials.gov, Case CCC; 216.286.2294; firstname.lastname@example.org.
FUNDING OPPORTUNITIESAmerican Cancer Society Institutional Research Grant Awards
The Case CCC, with funds from its American Cancer Society Institutional Research Grant (IRG), will provide seed money to foster cancer research by junior faculty who have no current national grant support of their own. Investigators in the Case School of Medicine and Cleveland Clinic Lerner College of Medicine as well as in other schools and colleges in the University are eligible. Grants, not to exceed $30,000 direct costs, will be awarded to investigators who intend to gather preliminary data to be used in seeking future and independently funded programs.
Letter of Intent Deadline: July 9
Alex's Lemonade Stand Foundation has released a call for applications for the following funding programs:
The Oncology Nursing Society Foundation is accepting applications for the following opportunities:
The Robert Wood Johnson Foundation Health & Society Scholars program provides two years of support to postdoctoral scholars at all stages of their careers to build the nation's capacity for research and leadership to address the multiple determinants of population health and contribute to policy change.
Deadline: September 21Case CCC Clinical Trials Protocol Specific Research Support Funding
The Case CCC is encouraging investigators to submit Letters of Intent for the Protocol Specific Research Support funding for Year 2012. The budgeted funds are for the conduct of early phase clinical trials and restricted to support research nurses and data managers directly involved in the conduct of these clinical trials. Studies developed jointly between UH and CCF with planned accrual at both institutions will be given a higher priority. Please direct questions and requests for information about the funding process to Katarzyna Karelus, Administrative Director, Case CCC Clinical Research Office, at 216.844.4176 or email@example.com.
NCI CANCER BULLETINJune 26, 2012
**All events are open to anyone interested in attending
Cancer Imaging Program Meeting canceled
Happy Independence Day!
Cancer Center Research in Progress will resume in September
Cancer Center Seminar Series will resume in September.
Hematology/Oncology Fellows will resume July 13.
Taussig Cancer Institute Grand Rounds will resume in September
Case CCC Calendar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
Cancer Center Retreat 2012: Preparation for Site Visit
Second Annual Imaging Solutions in Cancer Management: A Case-Based Conference
National GvHD Health Symposium
ADDITIONAL UPCOMING SEMINARS & EVENTS
Ninth International Conference of the Society for Integrative Oncology
Biennial Science of Global Prostate Cancer Disparities conference
Pacific Symposium on Biocomputing 2013
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Mesothelioma Applied Research Foundation
DOD Lung Cancer Research Program Concept Award
NIH BULLETIN – Notices and Funding Opportunities
Biomarkers for Early Detection of Hematopoietic Malignancies (R21) (PA-12-220)
Biomarkers for Early Detection of Hematopoietic Malignancies (R01) (PA-12-221)
Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01) (PAR-11-150)
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!
Send items to firstname.lastname@example.org.